To the Wefunder Community,
Many of our investors have been from the Wefunder family and thus we want to share additional information about our status with those who may be considering an investment in our technology.
There are 2 sides to addressing the HIV pandemic – the first is our current focus, namely a therapy for those who have the virus. The second is a vaccine that would prevent a person from ever becoming infected. Our technology opens the doors to both.
As the first, namely the production and final testing of a human monoclonal antibody that neutralizes the HIV virus, we will be completing 3 steps in the next 24 months taking us through animal trials proving the efficacy of our therapy. These steps are (1) final sequencing of the monoclonal antibody to produce the recombinant form of the antibody that is necessary for human application, (2) testing of that recombinant (with our partner at the Univ. of South Florida) against multiple strains of the virus to prove efficacy equivalent to the parent antibody and (3) animal trials (at MD Anderson Keeling Institute in Texas). At or before this point, we expect to partner with Pharma to complete human trials.
As to the second side of our technology, namely production of a vaccine that would prevent anyone from contracting the virus, we have last week signed a Confidentiality Agreement with the company that is the world’s largest producer of vaccines. This company has an interest in our technology and we recognize its leadership and world recognized leadership in the biotech world. As I mentioned, our technology opens the doors to both treatment of those who have the virus and a vaccine against contracting the virus.
Under the Confidentiality Agreement now in place, we are beginning discussions as to a joint effort to both produce an anti-HIV vaccine as well as complete the development of and animal and human trials of our monoclonal antibody. With regard to these discussions (as well as discussions with other big Pharma companies), your investment will support our amassing more confirming data to foster partnering with such companies.
Also, our NIH grant application is pending and the U.S. Congress recently increased the NIH budget for the next 5 months by an additional $2 Billion to support medical research. This is a benefit to all grant applicants - including us. Our application is currently pending and awardees will be named later this year.
Let me know if you have any questions. And give us consideration as you consider investing.
Charles Cotropia
CEO BioClonetics Immunotherapeutics, Inc.
Our video - https://youtu.be/SpCIISMiTXE